News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
333,390 Results
Type
Article (20029)
Company Profile (128)
Press Release (313233)
Multimedia
Podcasts (70)
Webinars (11)
Section
Business (105398)
Career Advice (879)
Deals (18534)
Drug Delivery (97)
Drug Development (50786)
Employer Resources (79)
FDA (7697)
Job Trends (7746)
News (185917)
Policy (17345)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (5)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (4)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (736)
Accelerated approval (3)
Adcomms (17)
Allergies (40)
Alliances (27842)
ALS (54)
Alzheimer's disease (639)
Antibody-drug conjugate (ADC) (88)
Approvals (7706)
Artificial intelligence (138)
Autoimmune disease (15)
Automation (4)
Bankruptcy (177)
Best Places to Work (5553)
BIOSECURE Act (13)
Biosimilars (95)
Biotechnology (57)
Bladder cancer (31)
Brain cancer (19)
Breast cancer (106)
Cancer (1034)
Cardiovascular disease (111)
Career advice (712)
Career pathing (20)
CAR-T (55)
Cell therapy (150)
Cervical cancer (5)
Clinical research (42664)
Collaboration (453)
Compensation (165)
Complete response letters (23)
COVID-19 (1099)
CRISPR (22)
C-suite (146)
Cystic fibrosis (58)
Data (1105)
Decentralized trials (2)
Denatured (18)
Depression (24)
Diabetes (138)
Diagnostics (1810)
Digital health (5)
Diversity (7)
Diversity, equity & inclusion (21)
Drug discovery (80)
Drug pricing (108)
Drug shortages (30)
Duchenne muscular dystrophy (59)
Earnings (39015)
Editorial (30)
Employer branding (10)
Employer resources (73)
Events (48555)
Executive appointments (432)
FDA (8270)
Featured Employer (23)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (308)
Gene editing (47)
Generative AI (18)
Gene therapy (144)
GLP-1 (588)
Government (1846)
Grass and pollen (2)
Guidances (18)
Healthcare (5904)
Huntington's disease (13)
IgA nephropathy (20)
Immunology and inflammation (82)
Indications (17)
Infectious disease (1180)
Inflammatory bowel disease (82)
Inflation Reduction Act (8)
Influenza (25)
Intellectual property (55)
Interviews (116)
IPO (7368)
IRA (45)
Job creations (2432)
Job search strategy (648)
Kidney cancer (7)
Labor market (21)
Layoffs (276)
Leadership (14)
Legal (4119)
Liver cancer (31)
Lung cancer (156)
Lymphoma (85)
Machine learning (2)
Management (30)
Manufacturing (197)
MASH (49)
Medical device (1963)
Medtech (1966)
Mergers & acquisitions (11418)
Metabolic disorders (489)
Multiple sclerosis (48)
NASH (20)
Neurodegenerative disease (49)
Neuropsychiatric disorders (20)
Neuroscience (949)
NextGen: Class of 2025 (2358)
Non-profit (906)
Northern California (1061)
Now hiring (20)
Obesity (306)
Opinion (190)
Ovarian cancer (33)
Pain (66)
Pancreatic cancer (35)
Parkinson's disease (86)
Partnered (11)
Patents (139)
Patient recruitment (45)
Peanut (16)
People (33442)
Pharmaceutical (74)
Pharmacy benefit managers (21)
Phase I (13359)
Phase II (18045)
Phase III (14501)
Pipeline (704)
Policy (115)
Postmarket research (1618)
Preclinical (4656)
Press Release (29)
Prostate cancer (59)
Psychedelics (16)
Radiopharmaceuticals (161)
Rare diseases (242)
Real estate (3175)
Recruiting (29)
Regulatory (12525)
Reports (22)
Research institute (819)
Resumes & cover letters (138)
Rett syndrome (1)
RNA editing (2)
RSV (25)
Schizophrenia (59)
Series A (57)
Series B (32)
Service/supplier (7)
Sickle cell disease (36)
Southern California (1017)
Special edition (15)
Spinal muscular atrophy (111)
Sponsored (12)
Startups (2009)
State (2)
Stomach cancer (9)
Supply chain (51)
Tariffs (21)
The Weekly (50)
United States (9974)
Vaccines (268)
Venture capitalists (27)
Weight loss (238)
Women's health (14)
Worklife (7)
Date
Today (52)
Last 7 days (236)
Last 30 days (1252)
Last 365 days (16832)
2025 (4645)
2024 (17672)
2023 (19637)
2022 (25865)
2021 (26639)
2020 (24870)
2019 (20057)
2018 (15587)
2017 (17253)
2016 (16202)
2015 (18801)
2014 (14787)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12738)
Location
Africa (409)
Alabama (23)
Alaska (1)
Arizona (65)
Arkansas (8)
Asia (24875)
Australia (3219)
California (2481)
Canada (1091)
China (319)
Colorado (95)
Connecticut (99)
Delaware (69)
Europe (51372)
Florida (433)
Georgia (54)
Idaho (16)
Illinois (243)
India (19)
Indiana (171)
Iowa (3)
Japan (115)
Kansas (62)
Kentucky (17)
Louisiana (2)
Maine (4)
Maryland (360)
Massachusetts (2096)
Michigan (48)
Minnesota (136)
Mississippi (1)
Missouri (27)
Montana (10)
Nebraska (11)
Nevada (16)
New Hampshire (8)
New Jersey (1013)
New Mexico (21)
New York (726)
North Carolina (492)
North Dakota (2)
Northern California (1061)
Ohio (81)
Oklahoma (5)
Oregon (21)
Pennsylvania (591)
Puerto Rico (11)
Rhode Island (16)
South America (608)
South Carolina (3)
Southern California (1017)
Tennessee (38)
Texas (327)
Utah (54)
Virginia (82)
Washington D.C. (43)
Washington State (214)
Wisconsin (20)
333,390 Results for "enyo pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome
ENYO Pharma (“ENYO”) announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical study of Vonafexor, a highly selective FXR agonist, for the treatment of Alport Syndrome.
January 3, 2024
·
3 min read
Government
Trump Tariffs Miss Pharma For Now, But Uncertainties Loom
Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector-specific duties “in the next month or so.”
April 3, 2025
·
2 min read
·
Tristan Manalac
Business
Five Biggest Drug Face-Offs in Pharma History
Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of rivalry that includes blockbuster drugs Keytruda, Humira and Eliquis.
April 9, 2025
·
9 min read
·
Tristan Manalac
Tariffs
Trump Tariff Pause Sparks Late-Day Rally for Pharma Stocks—But Not All
Pharma stocks went on a wild ride Wednesday amid whiplashing tariff threats from the U.S. president.
April 10, 2025
·
2 min read
·
Annalee Armstrong
Clinical research
Pharma R&D Returns Grow Again, But Deloitte Warns Progress is ‘Fragile’
Deloitte urged pharma executives to “be bold” in a new report tracking the top 20 pharmaceutical companies’ R&D performance.
March 27, 2025
·
3 min read
·
Annalee Armstrong
Press Releases
Traws Pharma Announces Management Updates
March 31, 2025
·
6 min read
Government
Trump Threatens Big Pharma With Tariffs—Unless They Reshore Manufacturing: Bloomberg
President Trump also refused to promise pharma execs that he would hamstring the IRA’s drug negotiation program.
February 24, 2025
·
2 min read
·
Tristan Manalac
Tariffs
Trump’s Tariffs Could Challenge Pharma’s Recession-Resistant Reputation
Long considered resistant to economic downturns, the pharmaceutical industry may face a greater challenge this time around as GLP-1s dominate and the population grows older.
April 8, 2025
·
5 min read
·
Annalee Armstrong
C-suite
GSK CEO Emma Walmsley Gets Pay Bump To Align With Pharma Peers
One of the lowest paid CEOs in pharma—and one of the only woman leading a top-tier giant—is set to receive up to $27.2 million in 2025.
February 27, 2025
·
2 min read
·
Annalee Armstrong
Government
Trump’s Whiplash Policies Keep Pharmas on Their Toes
As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives find themselves faced with policy questions ranging from the Inflation Reduction Act to RFK Jr.
February 12, 2025
·
4 min read
·
Annalee Armstrong
1 of 33,339
Next
